4 news items
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
environmental factors, genetics, and intestinal microbiota may contribute to the development of UC or CD
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
TAK
26 Feb 24
medical and environmental waste. BE will ramp up to a manufacturing capacity of up to 50 million doses a year, accelerating Takeda's efforts
FDA Approves Takeda's EOHILIA, The First And Only Oral Treatment In The U.S. For Eosinophilic Esophagitis
TAK
12 Feb 24
is unknown, it is believed to be triggered by a variety of stimuli including certain foods and environmental allergens.5,6 The chronic inflammation of EoE can
- Prev
- 1
- Next